Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Celltrion has decided to participate in a rights issue by its US subsidiary, Celltrion USA, Inc., investing approximately KRW 782.4B (4.45% of total equity) to fund the acquisition of a US API manufacturing facility and provide working capital.
📊 [Key Disclosure Details & Financial Summary]
- Disclosure Title: Decision on Acquisition of Shares and Equity Securities of Other Corporation
- Issuing Company (Target Entity): Celltrion USA, Inc. (US Affiliate / CEO: Bon-Joong Kim / Main Business: Pharmaceutical Wholesale & Retail)
- Acquisition Details:
- Number of Shares Acquired: 100 common shares
- Acquisition Amount: KRW 782,399,840,000 (approx. KRW 782.4B / USD 532,100,000)
- Applied Exchange Rate: Initial basic exchange rate on December 11, 2025 (USD/KRW 1,470.40)
- Acquisition-to-Equity Ratio: 4.45% (Based on consolidated total equity of KRW 17,580,062,368,691 at FY2024 end)
- Post-Acquisition Shareholding & Ownership: 3,150 common shares (100% ownership)
- Method of Acquisition: Participation in rights offering to existing shareholders (Cash acquisition)
- Purpose of Acquisition: Funding for Celltrion USA, Inc. to acquire securities of another entity (a US API manufacturing facility entity) and secure working capital
- Investment Schedule (Tranche Execution):
- 1st Tranche: USD 445,800,000 / Scheduled Date: December 18, 2025
- 2nd Tranche: USD 86,300,000 / Scheduled Period: During 2026
- Board Resolution Date: December 11, 2025 (All 8 outside directors attended)
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of 1st Tranche Capital Injection on December 18, 2025 and 2026 Progress
This disclosure details Celltrion’s decision to inject approx. KRW 782.4B into its 100% owned US subsidiary, Celltrion USA, Inc., in tranches to acquire a US API manufacturing facility, making it important to monitor the execution of the 1st tranche on December 18, 2025 and the subsequent 2nd tranche during 2026. Tracking the capital injection schedule ensures verification of capital execution and investment progress. Execution updates and capital contribution status can be verified under ‘Investments in Other Corporations’ in upcoming periodic filings (Quarterly, Half-Yearly, or Annual Business Reports) or through subsequent regulatory disclosures.
📢 Disclaimer & Source Information
Source: This content was newly generated and structured based on official data submitted to the Data Analysis, Retrieval and Transfer System (DART) of the Financial Supervisory Service.
Investment Risk Notice: This information is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright concerns, please contact ksb220805@gmail.com.
